Close Menu


News and analysis on diagnostic technologies and applications.

Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.

Mutated KRAS protein has been notoriously difficult to target with drugs, but MD Anderson researchers are trying to get at KRAS mRNA using exosomes.

Following the accelerated approval for tazemetostat last month, the new supplement application could poise it as the first EZH2 inhibitor for follicular lymphoma.